Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)

Market Cap	2.32B
Revenue (ttm)	665.09M
Net Income (ttm)	137.30M
Shares Out	n/a
EPS (ttm)	2.57
PE Ratio	16.88
Forward PE	n/a
Dividend	0.75 (1.38%)
Ex-Dividend Date	Jul 8, 2024

Volume	1,760
Average Volume	6,188
Open	54.60
Previous Close	54.65
Day's Range	54.60 - 55.25
52-Week Range	37.14 - 79.76
Beta	0.44
RSI	32.37
Earnings Date	Feb 25, 2025

About LON:0ILL

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Nepar...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1946
• Employees: 2,111
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2023, LON:0ILL's revenue was 829.51 million, an increase of 1.44% compared to the previous year's 817.70 million. Earnings were 170.34 million, a decrease of -14.69%.

Financial numbers in EUR